StockData
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. (CRDF) shareholders

CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.85−0.04 (-4.46%)

Close on Nov 20, 2026Market cap $66.34MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
24.2%
19M of 78M shares
Institutional holders
104
20 new, 31 sold out
Net institutional buying
-6M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $1.12M

Shares held by institutions

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of CRDFValueChange% of portfolio
Laurion Capital Management LP3,098,2993.98%$4.03M+451,5610.10%
Vanguard Capital Management LLC2,895,5923.72%$3.76M+39,6260.00%
Pfizer Inc2,411,5753.10%$3.01M–1.77%
Franklin Resources Inc1,205,8031.55%$1.57M–0.00%
BlackRock, Inc.972,8731.25%$1.26M−3,008,5140.00%
Blair William & Co/Il912,5131.17%$1.19M−9,8940.00%
Geode Capital Management, LLC820,0621.05%$1.07M−779,6010.00%
UBS Group AG638,6990.82%$830.31K+238,1230.00%
Jane Street Group, LLC607,9000.78%$790.27K+567,7950.00%
Vanguard Fiduciary Trust Co410,6020.53%$533.78K−35,6230.00%
Aqr Capital Management LLC346,3530.45%$450.26K+280,1970.00%
State Street Corp331,3950.43%$430.81K−855,5520.00%
Hrt Financial LP272,7860.35%$354.00KNew0.00%
Flputnam Investment Management Co247,4740.32%$321.72K−347,6530.00%
Morgan Stanley246,0950.32%$319.92K+189,7890.00%
Bnp Paribas Arbitrage, Snc228,4610.29%$297.00K+215,3850.00%
X-Square Capital, LLC205,7000.26%$267.00KNew0.07%
Gsa Capital Partners Llp173,2740.22%$225.00K+50,2660.01%
Marshall Wace, Llp162,2140.21%$210.88KNew0.00%
Bank of New York Mellon Corp161,6890.21%$210.20K−141,7390.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202610419M24.2%20 / 3526 / 313M9M
Q1 202611725M31.6%23 / 3037 / 145M4M
Q4 202511027M35.0%17 / 2534 / 184M2M
Q3 202511225M32.4%19 / 3329 / 203M7M
Q2 202511429M37.1%18 / 4523 / 196M9M
Q1 202511632M41.6%17 / 4917 / 178M3M
Q4 202411728M36.1%37 / 3917 / 317M1M
Q3 20248313M16.4%9 / 2524 / 154M2M
Q2 20249013M16.9%29 / 3312 / 167M2M
Q1 2024779M11.3%28 / 1710 / 64M0M
Q4 2023555M6.8%7 / 913 / 70M0M
Q3 2023555M6.9%7 / 815 / 40M1M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

95 funds held CRDF in Q1 2026, 66% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of CRDFValue% of fundAs of
Vanguard Total Stock Market Index Fund2,073,1262.66%$2.70M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund759,3210.98%$987.12K0.00%Jun 30, 2026
Franklin Biotechnology Discovery Fund438,9610.56%$375.49K0.03%Jul 31, 2026
Fidelity Extended Market Index Fund363,3880.47%$690.44K0.00%May 31, 2026
Vanguard Russell 2000 Index Fund324,8980.42%$617.31K0.00%May 31, 2026
iShares Micro-Cap ETF221,6890.28%$288.20K0.02%Jun 30, 2026
Fidelity Total Market Index Fund114,1370.15%$216.86K0.00%May 31, 2026
Fidelity Series Total Market Index Fund100,7430.13%$191.41K0.00%May 31, 2026
Small Company Growth Portfolio72,0570.09%$93.67K0.01%Jun 30, 2026
Goldman Sachs Absolute Return Tracker Fund46,2420.06%$60.11K0.00%Jun 30, 2026
Vanguard Balanced Index Fund35,4180.05%$46.04K0.00%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund34,6460.04%$65.83K0.00%May 31, 2026
Fidelity ZERO Total Market Index Fund30,5910.04%$26.17K0.00%Jul 31, 2026
Vanguard Russell 2000 Growth Index Fund28,2950.04%$53.76K0.00%May 31, 2026
Vanguard Institutional Total Stock Market Index Fund27,7270.04%$36.05K0.00%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Mani MohindruChief Executive Officer, Director59,0670.08%Jul 16, 2026
Mark ErlanderChief Executive Officer, Director24,4810.03%Mar 13, 2025
Leila AllandChief Medical Officer––Oct 27, 2026
Ajay AggarwalChief Operating Officer––Apr 28, 2026
Tod SmealChief Scientific Officer––Apr 16, 2026
Joshua B. MuntnerChief Financial Officer5000.00%Apr 16, 2026
Brigitte Ute LindsayChief Accounting Officer27,4310.04%Feb 18, 2026
Roger SidhuChief Medical Officer––Jul 8, 2025
Fairooz KabbinavarChief Medical Officer––Mar 13, 2025
James E. LevineChief Financial Officer127,7160.16%Mar 13, 2025
Gary W. PaceDirector3,389,3374.36%Jul 16, 2026
Renee P. TannenbaumDirector20,0000.03%Jun 15, 2026
James O. ArmitageDirector27,4900.04%Jun 15, 2026
Lale WhiteDirector113,7880.15%Jun 15, 2026
Rodney S. MarkinDirector31,0600.04%Jun 15, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Mani Mohindru
Chief Executive Officer, Director
Jul 14, 2026Buy+34,364$1.46$50.17K59,067
Gary W. Pace
Director
Jul 14, 2026Buy+687,285$1.46$1.00M2,043,661
Gary W. Pace
Director
Jun 18, 2026Buy+30,000$1.22$36.60K1,356,376
Mani Mohindru
Chief Executive Officer, Director
Jun 18, 2026Buy+24,703$1.21$29.89K24,703
Gary W. Pace
Director
Jul 30, 2025Buy+15,000$2.45$36.75K1,345,676
Gary W. Pace
Director
Jul 30, 2025Buy+275,000$2.45$673.75K1,330,676
James E. Levine
Chief Financial Officer
Dec 18, 2024Buy+2,400$5.00$12.00K67,716
James E. Levine
Chief Financial Officer
Dec 17, 2024Buy+2,752$5.42$14.92K65,316
James E. Levine
Chief Financial Officer
Dec 16, 2024Buy+2,564$3.83$9.82K62,564
Renee P. Tannenbaum
Director
Dec 12, 2024Buy+10,000$3.42$34.20K20,000
Gary W. Pace
Director
Dec 11, 2024Buy+350,115$2.60$910.30K1,047,876
Gary W. Pace
Director
Dec 11, 2024Buy+11,500$2.60$29.90K1,059,376
Gary W. Pace
Director
Dec 19, 2023Buy+30,000$1.37$41.10K697,761
Gary W. Pace
Director
Nov 10, 2023Buy+22,950$0.98$22.49K667,761
Mark Erlander
Chief Executive Officer, Director
Nov 25, 2022Buy+10,000$1.43$14.30K24,481
Lale White
Director
Sep 19, 2022Buy+15,000$1.64$24.60K113,788
James O. Armitage
Director
Sep 16, 2022Buy+13,000$1.56$20.28K13,000
James E. Levine
Chief Financial Officer
Sep 16, 2022Buy+30,000$1.56$46.80K60,000
Renee P. Tannenbaum
Director
Sep 15, 2022Buy+3,600$1.72$6.19K10,000
Renee P. Tannenbaum
Director
Sep 15, 2022Buy+6,400$1.72$11.01K6,400
Gary W. Pace
Director
Sep 15, 2022Buy+150,000$1.71$256.50K644,811
Lale White
Director
Jul 5, 2022Option exercise+28,858$2.60$75.03K98,788
Gary W. Pace
Director
Sep 21, 2021Buy+30,000$6.75$202.50K494,811
James E. Levine
Chief Financial Officer
Sep 10, 2021Buy+5,000$6.32$31.60K30,000
James E. Levine
Chief Financial Officer
Sep 10, 2021Buy+5,000$6.35$31.75K25,000
James E. Levine
Chief Financial Officer
Sep 10, 2021Buy+10,000$6.38$63.80K20,000
James E. Levine
Chief Financial Officer
Sep 10, 2021Buy+5,000$6.75$33.75K10,000
James E. Levine
Chief Financial Officer
Sep 10, 2021Buy+5,000$6.62$33.10K5,000
Rodney S. Markin
Director
Mar 26, 2021Buy+2,900$10.32$29.93K23,879
Gary W. Pace
Director
Mar 23, 2021Buy+5,000$10.20$51.00K459,811
Gary W. Pace
Director
Mar 23, 2021Buy+2,500$10.31$25.78K464,811
Gary W. Pace
Director
Mar 23, 2021Buy+2,500$10.21$25.53K462,311
Vicki Kelemen
Exec. VP and COO
Mar 23, 2021Buy+960$10.31$9.90K6,053
Gary S. Jacob
Director
Mar 23, 2021Buy+1,900$10.42$19.80K21,452
Gary S. Jacob
Director
Mar 23, 2021Buy+470$10.40$4.89K21,922
Mark Erlander
Chief Executive Officer
Mar 23, 2021Buy+965$10.34$9.98K14,481
John P. Brancaccio
Director
Mar 22, 2021Buy+3,000$10.95$32.85K12,260
James O. Armitage
Director
Mar 19, 2021Buy+4,000$10.82$43.28K14,490
Gary W. Pace
Director
Mar 18, 2021Buy+2,000$10.54$21.08K454,811
Gary W. Pace
Director
Mar 18, 2021Buy+1,000$10.58$10.58K452,811
Gary W. Pace
Director
Mar 4, 2021Buy+1,500$9.27$13.91K451,811
Mark Erlander
Chief Executive Officer
Jan 2, 2021Tax withholding−113––13,516
Mark Erlander
Chief Executive Officer
Jan 2, 2021Option exercise+260––13,629
Vicki Kelemen
Exec. VP and COO
Jan 2, 2021Tax withholding−31––5,093
Vicki Kelemen
Exec. VP and COO
Jan 2, 2021Option exercise+70––5,124
Vicki Kelemen
Exec. VP and COO
Nov 23, 2020Sale−35,321$18.60$656.97K5,054
Vicki Kelemen
Exec. VP and COO
Nov 23, 2020Option exercise+35,321$2.48$87.60K40,375
Gary W. Pace
Director
Sep 16, 2020Buy+1,700$5.69$9.67K449,461
Gary W. Pace
Director
Sep 16, 2020Buy+850$5.71$4.85K450,311
James O. Armitage
Director
May 14, 2020Buy+10,490$1.43$15.00K10,490
Mark Erlander
Chief Executive Officer
May 14, 2020Buy+6,993$1.43$10.00K13,369
Rodney S. Markin
Director
May 14, 2020Buy+20,979$1.43$30.00K28,160
Lale White
Director
May 14, 2020Buy+69,930$1.43$100.00K69,930
John P. Brancaccio
Director
May 14, 2020Buy+6,993$1.43$10.00K9,260
Gary S. Jacob
Director
May 14, 2020Buy+17,483$1.43$25.00K19,552
Thomas Adams Phd
Director
May 14, 2020Buy+13,986$1.43$20.00K18,875
Gary W. Pace
Director
May 11, 2020Buy+447,761$1.34$600.00K447,761
Mark Erlander
Chief Scientific Officer
Jan 3, 2020Tax withholding−116––6,376
Mark Erlander
Chief Scientific Officer
Jan 3, 2020Tax withholding−552––6,231
Mark Erlander
Chief Scientific Officer
Jan 2, 2020Option exercise+261––6,492

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
16.58%
12M shares short
Days to cover
30.8
At 0M shares a day
Change since last report
+1.2%
From 12M shares
Short volume, 20 days
54.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cardiff Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 37,995 shares on Aug 25, 2026 over the last 90 days.

See a number that looks wrong?